Pentoxyphilline Versus Fecal Microbiota Therapy in Severe Alcoholic Hepatitis
Status:
Completed
Trial end date:
2016-07-27
Target enrollment:
Participant gender:
Summary
Treatment for severe alcoholic hepatitis patients not eligible for steroid therapy is a
dilemma. Pentoxyfilline has been shown to have no improvement in outcomes as per current
studies and liver transplantation is with great risk of recidivism in this difficult to treat
cohort of patients. Dysbiosis forms the central role in severe alcoholic hepatitis patients
and modulation of gut microbiota by way of healthy donor fecal transplantation could prove to
be a novel way to treating these patients who are ineligible for standard therapy. This study
utilizes correction of dysbiosis in severe alcoholic hepatitis and surveys outcomes with the
same with respect to survival and liver disease severity scores.